Literature DB >> 16077349

Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.

Hee-Seung Chin1, Tae-Sung Park, Yeon-Sung Moon, Jung-Hyub Oh.   

Abstract

PURPOSE: To study the difference in clearance of intravitreal triamcinolone acetonide quantitatively between vitrectomized and nonvitrectomized eyes.
METHODS: Eighty-four eyes of 42 rabbits were divided in 2 groups: 42 right eyes underwent standard pars plana vitrectomy (vitrectomized group), and 42 left eyes were not operated on (nonvitrectomized group). All eyes received intravitreal injections with 0.1 mL (0.3 mg) of triamcinolone acetonide. Every 12 eyes were obtained by killing 6 rabbits 1, 2, 4, 7, 12, 20, or 30 days after intravitreal injection. Each eye was enucleated and immediately frozen at -70 degrees C. The frozen vitreous was prepared for measuring the concentration of triamcinolone acetonide. Triamcinolone acetonide was quantified by high-performance liquid chromatography and ultraviolet absorbance detection.
RESULTS: After 30 days, triamcinolone acetonide was detected only in 1 eye (0.22 microg/mL) in the vitrectomized group compared with 4 of 6 eyes (0.92 +/- 1.25 microg/mL) in the nonvitrectomized group. The coefficient of logarithmic regression was -0.12 in the vitrectomized group and -0.08 in the nonvitrectomized group. Triamcinolone acetonide decreased 1.5 times more rapidly in the vitrectomized group than in the nonvitrectomized group. The half-life of triamcinolone acetonide was 1.57 days in the vitrectomized group and 2.89 days in the nonvitrectomized group.
CONCLUSION: Intravitreal triamcinolone acetonide decreases more rapidly in the vitrectomized eye than in the nonvitrectomized eye. Therefore, the faster clearance of intravitreal triamcinolone acetonide must be considered when planning intravitreal injection of triamcinolone acetonide in the vitrectomized eye.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16077349     DOI: 10.1097/00006982-200507000-00002

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  77 in total

1.  Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.

Authors:  Dong Ho Park; Jae Pil Shin; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

2.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

3.  RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Susan B Bressler; Michele Melia; Adam R Glassman; Talat Almukhtar; Lee M Jampol; Michel Shami; Brian B Berger; Neil M Bressler
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

4.  Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis.

Authors:  L Pelegrín; M S de la Maza; B Molins; J Ríos; A Adán
Journal:  Eye (Lond)       Date:  2015-05-22       Impact factor: 3.775

5.  Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Authors:  Ryo Terao; Kentaro Yuda; Kayo Kure; Tatsuya Inoue; Hiroshi Ohtsu; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2014-01-10       Impact factor: 2.447

6.  Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

Authors:  Rohit Bisht; Abhirup Mandal; Ilva D Rupenthal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

7.  Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.

Authors:  M Elizabeth Hartnett; David J Martiniuk; Yuta Saito; Pete Geisen; Lynda J Peterson; Janet R McColm
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

8.  The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice.

Authors:  Dennis Y Tse; Seong Jae Kim; Inyoung Chung; Feng He; Theodore G Wensel; Samuel M Wu
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

Review 9.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

10.  Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema.

Authors:  Akiko Kogure; Kishiko Ohkoshi; Shunsuke Kogure; Tatsuo Yamaguchi; Shoji Kishi
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.